Review





Similar Products

interleukin 1 receptor antagonist il 1ra  (MedChemExpress)
93
MedChemExpress interleukin 1 receptor antagonist il 1ra
Interleukin 1 Receptor Antagonist Il 1ra, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/interleukin 1 receptor antagonist il 1ra/product/MedChemExpress
Average 93 stars, based on 1 article reviews
interleukin 1 receptor antagonist il 1ra - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
il-1 receptor antagonist  (Dawley Inc)
90
Dawley Inc il-1 receptor antagonist
Effects of ELS on microglia and the DA systems in key brain regions and mediated behavioral effects
Il 1 Receptor Antagonist, supplied by Dawley Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/il-1 receptor antagonist/product/Dawley Inc
Average 90 stars, based on 1 article reviews
il-1 receptor antagonist - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
mouse il 1ra csb e10395m kits  (Cusabio)
93
Cusabio mouse il 1ra csb e10395m kits
Effects of ELS on microglia and the DA systems in key brain regions and mediated behavioral effects
Mouse Il 1ra Csb E10395m Kits, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse il 1ra csb e10395m kits/product/Cusabio
Average 93 stars, based on 1 article reviews
mouse il 1ra csb e10395m kits - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
human il 1ra  (Cusabio)
93
Cusabio human il 1ra
Effects of ELS on microglia and the DA systems in key brain regions and mediated behavioral effects
Human Il 1ra, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human il 1ra/product/Cusabio
Average 93 stars, based on 1 article reviews
human il 1ra - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
il 1 receptor antagonist  (Cusabio)
93
Cusabio il 1 receptor antagonist
Effects of ELS on microglia and the DA systems in key brain regions and mediated behavioral effects
Il 1 Receptor Antagonist, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/il 1 receptor antagonist/product/Cusabio
Average 93 stars, based on 1 article reviews
il 1 receptor antagonist - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
il-1 receptor antagonist anakinra  (Swedish Orphan Biovitrum)
90
Swedish Orphan Biovitrum il-1 receptor antagonist anakinra
<t>Anakinra</t> treatment reduces the genotoxicity risk associated with the gene-editing procedure (A) Visualization of chromosomal translocation genome wide by CAST-Seq. (B and C) Copies of AAVS1 sequences per human genome 800 bp downstream to the target site in individual colonies generated by edited mPB HSPCs (B: n = 46, 93, 97, 93, and 85) or CB HSPCs (C: n = 48, 91, 92, 98, and 97) from 3 independent donors. LME, linear-mixed model. (D) Mutational rate of total variants in the indicated conditions from BM-derived CD34 + HSPCs of mice from one independent experiment from I ( n = 6, 6, 5, and 4); Kruskal-Wallis test. (E) Percentage of single-nucleotide variants (SNVs), deletions (DELs), and insertions (INSs) in BM-derived CD34 + HSPCs retrieved from mice in (D). n = 6, 6, 5, and 4; Kruskal-Wallis test; mean ± SEM. (F) Relative proportion (percentages) of SNV types in mice in (E). n = 6, 6, 5, and 4; Kruskal-Wallis test; mean ± SEM. (G) Percentage of variants with high (HIGH), moderate (MODERATE), or low (LOW) impact found in BM-derived CD34 + HSPCs retrieved from mice in (D) ( n = 6, 6, 5, and 4); Kruskal-Wallis test; mean ± SEM. (H and I) Quantification and Circos plots representing variants in clonal hematopoiesis (CH)-associated genes (H) or cancer-associated genes (I) ( n = 6, 6, 5, and 4); Kruskal-Wallis test. p values: ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001. If not indicated, results are not significant (ns). Unless otherwise specified, lines indicate median values. (−): HS/AAV6 condition.
Il 1 Receptor Antagonist Anakinra, supplied by Swedish Orphan Biovitrum, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/il-1 receptor antagonist anakinra/product/Swedish Orphan Biovitrum
Average 90 stars, based on 1 article reviews
il-1 receptor antagonist anakinra - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
il-1 receptor antagonist anakinra kineret  (Swedish Orphan Biovitrum)
90
Swedish Orphan Biovitrum il-1 receptor antagonist anakinra kineret
<t>Anakinra</t> treatment reduces the genotoxicity risk associated with the gene-editing procedure (A) Visualization of chromosomal translocation genome wide by CAST-Seq. (B and C) Copies of AAVS1 sequences per human genome 800 bp downstream to the target site in individual colonies generated by edited mPB HSPCs (B: n = 46, 93, 97, 93, and 85) or CB HSPCs (C: n = 48, 91, 92, 98, and 97) from 3 independent donors. LME, linear-mixed model. (D) Mutational rate of total variants in the indicated conditions from BM-derived CD34 + HSPCs of mice from one independent experiment from I ( n = 6, 6, 5, and 4); Kruskal-Wallis test. (E) Percentage of single-nucleotide variants (SNVs), deletions (DELs), and insertions (INSs) in BM-derived CD34 + HSPCs retrieved from mice in (D). n = 6, 6, 5, and 4; Kruskal-Wallis test; mean ± SEM. (F) Relative proportion (percentages) of SNV types in mice in (E). n = 6, 6, 5, and 4; Kruskal-Wallis test; mean ± SEM. (G) Percentage of variants with high (HIGH), moderate (MODERATE), or low (LOW) impact found in BM-derived CD34 + HSPCs retrieved from mice in (D) ( n = 6, 6, 5, and 4); Kruskal-Wallis test; mean ± SEM. (H and I) Quantification and Circos plots representing variants in clonal hematopoiesis (CH)-associated genes (H) or cancer-associated genes (I) ( n = 6, 6, 5, and 4); Kruskal-Wallis test. p values: ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001. If not indicated, results are not significant (ns). Unless otherwise specified, lines indicate median values. (−): HS/AAV6 condition.
Il 1 Receptor Antagonist Anakinra Kineret, supplied by Swedish Orphan Biovitrum, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/il-1 receptor antagonist anakinra kineret/product/Swedish Orphan Biovitrum
Average 90 stars, based on 1 article reviews
il-1 receptor antagonist anakinra kineret - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
il 1 receptor antagonist  (MedChemExpress)
94
MedChemExpress il 1 receptor antagonist
<t>Anakinra</t> treatment reduces the genotoxicity risk associated with the gene-editing procedure (A) Visualization of chromosomal translocation genome wide by CAST-Seq. (B and C) Copies of AAVS1 sequences per human genome 800 bp downstream to the target site in individual colonies generated by edited mPB HSPCs (B: n = 46, 93, 97, 93, and 85) or CB HSPCs (C: n = 48, 91, 92, 98, and 97) from 3 independent donors. LME, linear-mixed model. (D) Mutational rate of total variants in the indicated conditions from BM-derived CD34 + HSPCs of mice from one independent experiment from I ( n = 6, 6, 5, and 4); Kruskal-Wallis test. (E) Percentage of single-nucleotide variants (SNVs), deletions (DELs), and insertions (INSs) in BM-derived CD34 + HSPCs retrieved from mice in (D). n = 6, 6, 5, and 4; Kruskal-Wallis test; mean ± SEM. (F) Relative proportion (percentages) of SNV types in mice in (E). n = 6, 6, 5, and 4; Kruskal-Wallis test; mean ± SEM. (G) Percentage of variants with high (HIGH), moderate (MODERATE), or low (LOW) impact found in BM-derived CD34 + HSPCs retrieved from mice in (D) ( n = 6, 6, 5, and 4); Kruskal-Wallis test; mean ± SEM. (H and I) Quantification and Circos plots representing variants in clonal hematopoiesis (CH)-associated genes (H) or cancer-associated genes (I) ( n = 6, 6, 5, and 4); Kruskal-Wallis test. p values: ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001. If not indicated, results are not significant (ns). Unless otherwise specified, lines indicate median values. (−): HS/AAV6 condition.
Il 1 Receptor Antagonist, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/il 1 receptor antagonist/product/MedChemExpress
Average 94 stars, based on 1 article reviews
il 1 receptor antagonist - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
il-1 receptor antagonist (il-1ra)  (Swedish Orphan Biovitrum)
90
Swedish Orphan Biovitrum il-1 receptor antagonist (il-1ra)
<t>Anakinra</t> treatment reduces the genotoxicity risk associated with the gene-editing procedure (A) Visualization of chromosomal translocation genome wide by CAST-Seq. (B and C) Copies of AAVS1 sequences per human genome 800 bp downstream to the target site in individual colonies generated by edited mPB HSPCs (B: n = 46, 93, 97, 93, and 85) or CB HSPCs (C: n = 48, 91, 92, 98, and 97) from 3 independent donors. LME, linear-mixed model. (D) Mutational rate of total variants in the indicated conditions from BM-derived CD34 + HSPCs of mice from one independent experiment from I ( n = 6, 6, 5, and 4); Kruskal-Wallis test. (E) Percentage of single-nucleotide variants (SNVs), deletions (DELs), and insertions (INSs) in BM-derived CD34 + HSPCs retrieved from mice in (D). n = 6, 6, 5, and 4; Kruskal-Wallis test; mean ± SEM. (F) Relative proportion (percentages) of SNV types in mice in (E). n = 6, 6, 5, and 4; Kruskal-Wallis test; mean ± SEM. (G) Percentage of variants with high (HIGH), moderate (MODERATE), or low (LOW) impact found in BM-derived CD34 + HSPCs retrieved from mice in (D) ( n = 6, 6, 5, and 4); Kruskal-Wallis test; mean ± SEM. (H and I) Quantification and Circos plots representing variants in clonal hematopoiesis (CH)-associated genes (H) or cancer-associated genes (I) ( n = 6, 6, 5, and 4); Kruskal-Wallis test. p values: ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001. If not indicated, results are not significant (ns). Unless otherwise specified, lines indicate median values. (−): HS/AAV6 condition.
Il 1 Receptor Antagonist (Il 1ra), supplied by Swedish Orphan Biovitrum, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/il-1 receptor antagonist (il-1ra)/product/Swedish Orphan Biovitrum
Average 90 stars, based on 1 article reviews
il-1 receptor antagonist (il-1ra) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
recombinant rat il-1 receptor type i (il-1ri) antagonist  (Millipore)
90
Millipore recombinant rat il-1 receptor type i (il-1ri) antagonist
<t>Anakinra</t> treatment reduces the genotoxicity risk associated with the gene-editing procedure (A) Visualization of chromosomal translocation genome wide by CAST-Seq. (B and C) Copies of AAVS1 sequences per human genome 800 bp downstream to the target site in individual colonies generated by edited mPB HSPCs (B: n = 46, 93, 97, 93, and 85) or CB HSPCs (C: n = 48, 91, 92, 98, and 97) from 3 independent donors. LME, linear-mixed model. (D) Mutational rate of total variants in the indicated conditions from BM-derived CD34 + HSPCs of mice from one independent experiment from I ( n = 6, 6, 5, and 4); Kruskal-Wallis test. (E) Percentage of single-nucleotide variants (SNVs), deletions (DELs), and insertions (INSs) in BM-derived CD34 + HSPCs retrieved from mice in (D). n = 6, 6, 5, and 4; Kruskal-Wallis test; mean ± SEM. (F) Relative proportion (percentages) of SNV types in mice in (E). n = 6, 6, 5, and 4; Kruskal-Wallis test; mean ± SEM. (G) Percentage of variants with high (HIGH), moderate (MODERATE), or low (LOW) impact found in BM-derived CD34 + HSPCs retrieved from mice in (D) ( n = 6, 6, 5, and 4); Kruskal-Wallis test; mean ± SEM. (H and I) Quantification and Circos plots representing variants in clonal hematopoiesis (CH)-associated genes (H) or cancer-associated genes (I) ( n = 6, 6, 5, and 4); Kruskal-Wallis test. p values: ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001. If not indicated, results are not significant (ns). Unless otherwise specified, lines indicate median values. (−): HS/AAV6 condition.
Recombinant Rat Il 1 Receptor Type I (Il 1ri) Antagonist, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant rat il-1 receptor type i (il-1ri) antagonist/product/Millipore
Average 90 stars, based on 1 article reviews
recombinant rat il-1 receptor type i (il-1ri) antagonist - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Journal: Neural Regeneration Research

Article Title: Emerging role of microglia in the developing dopaminergic system: Perturbation by early life stress

doi: 10.4103/NRR.NRR-D-24-00742

Figure Lengend Snippet: Effects of ELS on microglia and the DA systems in key brain regions and mediated behavioral effects

Article Snippet: , IL-1 receptor antagonist , Sprague–Dawley rat, M , Intracerebral injection of LPS (1 mg/kg) at PND5 , Intracerebral injection of IL-1 receptor antagonist (0.1 mg/kg) at PND5 , SN , IL-1R antagonist reduces microglial activation and IL-1β, IL-6, TNF-α levels, attenuating dopamine neuron damage. , Pang et al., 2015.

Techniques: Inhibition

Anakinra treatment reduces the genotoxicity risk associated with the gene-editing procedure (A) Visualization of chromosomal translocation genome wide by CAST-Seq. (B and C) Copies of AAVS1 sequences per human genome 800 bp downstream to the target site in individual colonies generated by edited mPB HSPCs (B: n = 46, 93, 97, 93, and 85) or CB HSPCs (C: n = 48, 91, 92, 98, and 97) from 3 independent donors. LME, linear-mixed model. (D) Mutational rate of total variants in the indicated conditions from BM-derived CD34 + HSPCs of mice from one independent experiment from I ( n = 6, 6, 5, and 4); Kruskal-Wallis test. (E) Percentage of single-nucleotide variants (SNVs), deletions (DELs), and insertions (INSs) in BM-derived CD34 + HSPCs retrieved from mice in (D). n = 6, 6, 5, and 4; Kruskal-Wallis test; mean ± SEM. (F) Relative proportion (percentages) of SNV types in mice in (E). n = 6, 6, 5, and 4; Kruskal-Wallis test; mean ± SEM. (G) Percentage of variants with high (HIGH), moderate (MODERATE), or low (LOW) impact found in BM-derived CD34 + HSPCs retrieved from mice in (D) ( n = 6, 6, 5, and 4); Kruskal-Wallis test; mean ± SEM. (H and I) Quantification and Circos plots representing variants in clonal hematopoiesis (CH)-associated genes (H) or cancer-associated genes (I) ( n = 6, 6, 5, and 4); Kruskal-Wallis test. p values: ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001. If not indicated, results are not significant (ns). Unless otherwise specified, lines indicate median values. (−): HS/AAV6 condition.

Journal: Cell Reports Medicine

Article Title: Senescence and inflammation are unintended adverse consequences of CRISPR-Cas9/AAV6-mediated gene editing in hematopoietic stem cells

doi: 10.1016/j.xcrm.2025.102157

Figure Lengend Snippet: Anakinra treatment reduces the genotoxicity risk associated with the gene-editing procedure (A) Visualization of chromosomal translocation genome wide by CAST-Seq. (B and C) Copies of AAVS1 sequences per human genome 800 bp downstream to the target site in individual colonies generated by edited mPB HSPCs (B: n = 46, 93, 97, 93, and 85) or CB HSPCs (C: n = 48, 91, 92, 98, and 97) from 3 independent donors. LME, linear-mixed model. (D) Mutational rate of total variants in the indicated conditions from BM-derived CD34 + HSPCs of mice from one independent experiment from I ( n = 6, 6, 5, and 4); Kruskal-Wallis test. (E) Percentage of single-nucleotide variants (SNVs), deletions (DELs), and insertions (INSs) in BM-derived CD34 + HSPCs retrieved from mice in (D). n = 6, 6, 5, and 4; Kruskal-Wallis test; mean ± SEM. (F) Relative proportion (percentages) of SNV types in mice in (E). n = 6, 6, 5, and 4; Kruskal-Wallis test; mean ± SEM. (G) Percentage of variants with high (HIGH), moderate (MODERATE), or low (LOW) impact found in BM-derived CD34 + HSPCs retrieved from mice in (D) ( n = 6, 6, 5, and 4); Kruskal-Wallis test; mean ± SEM. (H and I) Quantification and Circos plots representing variants in clonal hematopoiesis (CH)-associated genes (H) or cancer-associated genes (I) ( n = 6, 6, 5, and 4); Kruskal-Wallis test. p values: ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001. If not indicated, results are not significant (ns). Unless otherwise specified, lines indicate median values. (−): HS/AAV6 condition.

Article Snippet: CB- or mPB-derived HSPCs were treated with 3.5 μg of p53 inhibitor ( GSE56 mRNA) co-electroporated with RNP complex, 50 ng/μL of IL-1 receptor antagonist Anakinra (Kineret, SOBI) and 25 μM InSolutionTM IKK-2 Inhibitor SC514 (Merck, 401485) administered immediately after the GE procedure.

Techniques: Translocation Assay, Genome Wide, Generated, Derivative Assay